the new protocol of palladium-catalyzed intermolecular
CꢀH addition to isatins by direct sp2 CꢀH activation was
built and the optimal reaction conditions were obtained by
using Pd(OAc)2 (10 mol %) as the catalyst, 2,20-bipyridine
(15mol %) astheligand in1mLofdioxanefor0.3 mmol of
1a, and 4 equiv of benzoxazole at 120 °C under an argon
atmosphere (for details, see Table S1 in Supporting In-
formation (SI)).
carcinoma cell line SMMC-7721 (Figure S1 in SI).10 The
results showed that the N-protection groups of benzyl and
the substituent group on the benzoxazole were the key to
the improvement of antitumor activity, and 2w yielded the
lowest IC50 value of 42 and 45 μM. Thus, from a diverse
array of structural modification and deprotection assays,
we were convinced that the activity of 2w would improve
and that we would locate the antihuman kidney cancer and
hepatocellular carcinoma target.
Having established optimal reaction conditions (Table S1,
entry 18), we further investigated the scope of isatins and
heteroarenes. As shown in Table 1, an investigation into
different N-protection groups revealed that methyl and
benzyl were appropriate for the reaction (2aꢀ2b), but tosyl
failed (2c). When the solvent was changed to DMF, the
N-free isatin has been converted into the desired prod-
uct 2d in 41% yield. Various substituted N-methylisatins
worked very well, and the corresponding products were
obtained in good to excellent yields regardless of the steric
hindrance and electronic properties of the substituents
(2eꢀ2o). Toourdelight, different substituted benzoxazoles
alsounderwent nucleophilicaddition smoothlyand readily
converted to the products in 76ꢀ97% yields (2pꢀ2v).
Moreover, the N-benzyl protected isatin reacted with
5-Cl-benzoxazole to afford the product 2w in 76% yield.
The reaction conditions displayed noteworthy tolerance to
the nitro group such that the desired products 2k and 2t
were afforded in 79% and 77% yields. Yet, other azoles
such as imidazole, benzothiazole, 2-phenyl-1,3,4-oxadiazole,
and their derivatives were also compatible with this trans-
formation, and the corresponding products were ob-
tained in moderate to excellent yields (2xꢀ2ad). It should
be noted that the product 2z was only afforded in a 45%
yield, presumably because the methyl group played a
negative role in CꢀH bond activation.
During the screening of solvents, we found that acetoni-
trile was activated instead of benzoxazole under initial
reaction conditions. Moreover, acetonitrile provided nu-
cleophilic addition to isatin toward the product of 3a in
67% yield. Further optimization indicated that the best
reaction condition is 10 mol % Pd(OAc)2 and 15 mol %
1,10-phenanthroline in the mixture of DMF and CH3CN
(1:1) at 100 °C. Use of these conditions improved the yield
of 3a to 87%. A survey of recent literature indicates that
activation of the sp3 CꢀH bond of acetonitrile has at-
tracted much attention, among some examples also in-
volved in nucleophilic addition to carbonyl by using Ru
and Cu complex catalysts in the presence of base or/and
special additives.11 Our protocol involves very different
activationpatterns, and itssuccess requiresneitheranextra
base nor an additive. Therefore, we decided to investigate
the scope of different substituted N-methylisatins within
our catalytic system. Indeed, our system displayed excel-
lent functional group tolerance, and the corresponding
products were obtainedingood to excellent yields (Table2,
entries 1ꢀ12). Furthermore, using our product of 3a as
starting material, we can easily synthesize (()-CPC-1 in
85% yield by reductive cyclization and methylation with
As new structural heterocycles, these acquired 3-azole-3-
hydroxy-2-oxindoles may possess antitumor potential on
the cellular level. The results of the preliminary biological
activity assay indicate that some of products do in fact
possess antitumor activity. Encouraged by this result,
we further evaluated the antitumor activity by using the
kidney cancer cell of A498 and human hepatocellular
Table 2. Nucleopilic Addition Different Isatins with CH3CNa,b
(9) For selected examples on CꢀH activation of azoles, see: (a) Do,
H. Q.; Khan, R. M. K.; Daugulis, O. J. Am. Chem. Soc. 2008, 130, 15185.
(b) Cho, S. H.; Kim, J. Y.; Lee, S. Y.; Chang, S. Angew. Chem., Int. Ed.
2009, 48, 9127. (c) Canivet, J.; Yamaguchi, J.; Ban, I.; Itami, K. Org.
Lett. 2009, 11, 1733. (d) Ackermann, L.; Althammer, A.; Fenner, S.
Angew. Chem., Int. Ed. 2009, 48, 201. (e) Xi, P. H.; Yang, F.; Qin, S.;
Zhao, D. B.; Lan, J. B.; Gao, G.; Hu, C. W.; You, J. S. J. Am. Chem. Soc.
2010, 132, 1822. (f) Zhang, L.; Cheng, J. H.; Ohishi, T.; Hou, Z. M.
Angew. Chem., Int. Ed. 2010, 49, 8670. (g) Wu, X. F.; Anbarasan, P.;
Neumann, H.; Beller, M. Angew. Chem., Int. Ed. 2010, 49, 7316. (h)
Kawano, T.; Hirano, K.; Satoh, T.; Miura, M. J. Am. Chem. Soc. 2010,
132, 6900. (i) Vechorkin, O.; Proust, V.; Hu, X. L. Angew. Chem., Int. Ed.
2010, 49, 3061. (j) Huang, J.; Chan, J.; Chen, Y.; Broths, C.; Baucom,
J. K. D.; Larsen, R. D.; Faul, M. M. J. Am. Chem. Soc. 2010, 132, 3674.
(k) Hachiya, H.; Hirano, K.; Satoh, T.; Miura, M. Angew. Chem., Int.
Ed. 2010, 49, 2202. (l) Han, W.; Mayer, P.; Ofial, A. R. Angew. Chem.,
Int. Ed. 2011, 50, 2178. (m) Kitahara, M.; Umeda, N.; Hirano, K.; Satoh,
T.; Miura, M. J. Am. Chem. Soc. 2011, 133, 2160. (n) Zhao, X.; Wu, G.;
Zhang, Y.; Wang, J. B. J. Am. Chem. Soc. 2011, 133, 3296. (o) Wu, G.;
Zhou, J.; Zhang, M.; Hu, P.; Su, W.-P. Chem. Commun. 2012, 48, 8964.
(p) Nishino, M.; Hirano, K.; Satoh, T.; Miura, M. Angew. Chem., Int.
Ed. 2012, 51, 6993. (q) Muto, K.; Yamaguchi, J.; Itami, K. J. Am. Chem.
Soc. 2012, 134, 169.
a The reaction was carried out with Pd(OAc)2 (10 mol %), Phen
(15 mol %), 1a (0.30 mmol), and acetonitrile (1.5 mL) with DMF
(1.5 mL) at 100 °C for 24 h under argon. b Yield of isolated product.
(10) (a) Ning, S.; Trisler, K.; Wessels, B. W.; Knox, S. J. Cancer 1997,
80, 2519. (b) Li, L.; Qi, Z.; Qian, J.; Bi, F.; Lv, J.; Xu, L.; Zhang, L.;
Chen, H.; Jia, R. Mol. Cell Biochem. 2010, 342, 125.
(11) (a) Culkin, D. A.; Hartwig, J. F. J. Am. Chem. Soc. 2002, 124,
9330. (b) You, J.; Verkade, J. G. Angew. Chem., Int. Ed. 2003, 42, 5051.
(c) Suto, Y.; Kumagai, N.; Matsunaga, S.; Kanai, M.; Shibasaki, M.
Org. Lett. 2003, 5, 3147. (d) Kumagai, N.; Matsunaga, S.; Shibasaki, M.
J. Am. Chem. Soc. 2004, 126, 13632. (e) Suto, Y.; Tsuji, R.; Kanai, M.;
Shibasaki, M. Org. Lett. 2005, 7, 3757. (f) Kumagai, N.; Matsunaga, S.;
Shibasaki, M. Tetrahedron. 2007, 63, 8598. (g) Wu, T.; Mu, X.; Liu, G. S.
Angew. Chem., Int. Ed. 2011, 50, 12578.
Org. Lett., Vol. XX, No. XX, XXXX
C